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O-GlcNAc transferase integrates glucose and glutamine metabolism and controls T cell 
self-renewal and malignant transformation 
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Abstract 
 
Sustained glucose and glutamine transport are essential for activated T lymphocytes to 
support ATP and macromolecule biosynthesis. We now show that glutamine and glucose also 
fuel an indispensible dynamic regulation of intracellular protein O-GlcNAcylation at key 
stages of T cell development, transformation and differentiation. Glucose and glutamine are 
precursors of UDP-GlcNAc, a substrate for cellular glycosyltransferases. Immune activated T 
cells contained higher concentrations of UDP-GlcNAc and increased intracellular protein O- 
GlcNAcylation controlled by the enzyme O-GlcNAc glycosyltransferase as compared to 
naïve cells. We identified Notch, the T cell antigen receptor and c-Myc as key controllers of 
T cell protein O-GlcNAcylation, via regulation of glucose and glutamine transport. Loss of 
O-GlcNAc transferase blocked T cell progenitor renewal, malignant transformation, and 
peripheral T cell clonal expansion. Nutrient-dependent signaling pathways regulated by O- 
GlcNAc glycosyltransferase are thus fundamental for T cell biology. 
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One function of antigen and cytokine controlled signaling pathways in T cells is to regulate 
expression of nutrient transporters and metabolic enzymes to meet the metabolic demands 
during thymus development and immune responses
1
. Increased capacity to transport glucose 
and amino acids is essential to fuel oxidative phosphorylation, glycolysis, and de novo 
protein synthesis in activated T cells. The supply of glucose, leucine and glutamine in T cells 
also controls the activity of mammalian Target of Rapamycin Complex 1 (mTORC1)
2-4
. 
Additionally, glutamine can be directed into glutaminolysis to produce key metabolic 
intermediates pyruvate and lactate, precursors for fatty acid biosynthesis and ATP production 
from the citric acid cycle
1,5
. 
One other metabolic route for glucose and glutamine is the hexosamine biosynthetic pathway 
(HBP), which controls the production of UDP-GlcNAc (uridine diphosphate N- 
acetylglucosamine). UDP-GlcNAc is metabolized by glycosyltransferases to produce 
glycoproteins, proteoglycans and glycolipids. It is also the donor substrate for O-GlcNAc 
transferase (OGT), a unique enzyme  that catalyzes the addition  of O-linked--N- 
acetylglucosamine (O-GlcNAc) to serine or threonine residues on intracellular proteins
6
. This 
post-translational modification is reversible and the cleavage of O-GlcNAc from modified 
proteins is controlled by a single glycoside hydrolase known as O-GlcNAcase (OGA)
6
. O- 
GlcNAcylation can compete with phosphorylation for modification of serine or threonine 
residues allowing dynamic crosstalk between these modifications, that can change the output 
of Ser/Thr kinase-mediated signaling pathways
7-9
. O-GlcNAcylation is an essential process 
that can also directly control protein stability, localization, transcriptional activity and 
multiple other cellular functions
6,10
. OGT is moreover indispensible for murine embryo 
development and for thymus development
11,12
. 
Precise regulation of glucose and glutamine transport is essential for T cells
4,13
. It has also 
been described that ConA activation of T cells causes transient increase of intracellular 
protein O-GlcNAcylation
14 
and c-Rel and NFAT have been reported to be OGT substrates in 
T cells
15,16
. However, there is little information about the regulation of the HBP or protein O- 
GlcNAcylation in T cells, or about the dynamics of O-GlcNAcylation in peripheral T cells. In 
the present study, we show that at key stages of T cell development and activation, as well as 
in malignant T cells, glucose and glutamine are directed through the HBP to support dynamic 
intracellular protein O-GlcNAcylation. We show that Notch, the T cell antigen receptor 
(TCR), and the transcription factor c-Myc regulate protein O-GlcNAcylation at different 
stages of T cell development and activation. We also show that OGT is critical for Notch- 
mediated self-renewal of T cell progenitors in the thymus; for T cell malignant 
transformation; and for the clonal expansion of TCR-activated peripheral T cells. Hence the 
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modification of proteins such as c-Myc by O-GlcNAcylation links nutrient transport to the 
control of T cell function: a previously unappreciated but essential role of glucose and 
glutamine metabolism in T cells. 
 
Results 
 
Increased UDP-GlcNAc synthesis in TCR-triggered T cells 
 
Triggering of the TCR on naïve T lymphocytes increases expression of glucose and glutamine 
transporters
5 
and glucose and glutamine transport (Fig. 1a)
4,17-19
. TCR-primed CD8
+ 
T cells 
cultured in interleukin 2 (IL-2) clonally expand and differentiate to cytotoxic T cells (CTLs) 
that have very high rates of glucose and glutamine transport (Fig. 1b). Similarly, there was 
increased glucose and glutamine transport in ‘TH1’ CD4
+ 
effector cells (Fig. 1b). Glucose 
and glutamine can be metabolized via the HBP to make UDP-GlcNAc (Fig. 1c). We therefore 
used liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ES-
MS/MS) to quantify UDP-GlcNAc content in T lymphocytes
20 
to explore whether immune 
activation modulates their intracellular UDP-GlcNAc pools. These experiments revealed 
that TCR triggering of CD8
+ 
T cells with cognate peptide induced  a  striking increase in 
cellular UDP-GlcNAc concentrations (Fig. 1d). Moreover in effector CTLs, concentrations 
of UDP-GlcNAc were ~ 7 × 10
8 
molecules per cell, a log increase compared to UDP-GlcNAc 
amounts in naïve T cells. There was also a significant increase in UDP- GlcNAc 
concentrations in activated CD4
+ 
T cells, with a 10-fold increase over naïve cells just 24 
hours after TCR triggering (Fig. 1e). Effector CD4
+ 
T cells had ~ 3 × 10
8 
UDP- GlcNAc 
molecules per cell, about half as much as CTLs, which correlated with the lower glucose 
and glutamine uptake measured in TH1 CD4
+ 
effectors as compared to CTLs (Fig. 1b). The 
production of UDP-GlcNAc was necessarily dependent on external glucose and glutamine 
supply (Fig. 1f). Importantly, the supply of glucosamine could vastly increase UDP-
GlcNAc concentrations in nutrient-starved T cells, consistent with the model that T 
cells control cellular levels of UDP-GlcNAc via the HBP, and that nutrient uptake and 
conversion to glucosamine-6-phosphate are rate-limiting in T cells (Fig.1c,g). 
 
Dynamic regulation of O-GlcNAcylation in T cells 
 
UDP-GlcNAc is a substrate for OGT, the enzyme that controls the modification of 
intracellular proteins by O-GlcNAc. We considered the possibility that changes in the 
availability of UDP-GlcNAc might promote changes in protein O-GlcNAcylation in immune 
activated T cells. Immunoblot analysis with an O-GlcNAc specific antibody (RL2) revealed a 
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strong increase in O-GlcNAcylation of multiple proteins in antigen receptor activated CD8
+ 
T cells compared to naïve T cells (Fig. 2a). Effector CTLs also had high levels of protein O- 
GlcNAcylation (Fig. 2b). Pre-treatment of the CTLs lysates with the bacterial O-GlcNAcase, 
CpOGA
21
, or antibody competition with N-Acetylglucosamine (GlcNAc), confirmed the 
specificity of the antibody for O-GlcNAcylated proteins (Fig. 2b). To quantitatively monitor 
protein O-GlcNAcylation during T cell activation we developed an intracellular flow 
cytometric assay with the RL2 antibody. Activated CTLs exhibited higher RL2 intracellular 
staining as compared to naïve T cells (Fig. 2c) and this staining was effectively competed by 
the free GlcNAc sugar (Fig. 2d). Treating permeabilized CTLs with CpOGA, which removes 
O-GlcNAc from proteins, reduced RL2 staining (Fig. 2e). There was no strong correlation 
between RL2 staining intensity and cell size (Fig. 2f). Importantly, there was no RL2 staining 
in non-permeabilized activated T cells (Fig. 2g) confirming that these RL2 analyses detect 
intracellular protein O-GlcNAcylation, and not surface protein glycosylation. 
Using this assay, we saw a rapid and sustained increase in RL2 staining in CD4
+ 
and CD8
+ 
T 
cells activated with CD3 and CD28 antibodies (Fig. 2h). There were also increases in RL2 
staining in OT-I TCR transgenic T cells triggered with their cognate peptide (Fig. 2i). TCR 
activation is regulated by the quantity and affinity of the TCR ligand and the increase in 
intracellular protein O-GlcNAcylation in TCR-activated OT-I cells was commensurate with 
the quality and quantity of the TCR ligand (Fig. 2i,j). We also found that activated T cells 
from mice infected with Listeria monocytogenes had enhanced protein O-GlcNAcylation as 
compared to non-activated T cells from the same mice (Fig. 2k,l). Thus in vitro and in vivo, T 
cells actively regulate intracellular protein O-GlcNAcylation. The increases in protein O- 
GlcNAcylation are relatively rapid responses (within 6 hours) to T cell activation and precede 
the increases in cell size and cell cycle progression that accompany T cell activation. 
To assess whether protein O-GlcNAcylation was dynamically regulated in T cells, CTLs 
were treated with a metabolic OGT inhibitor (4AC-5S-GlcNAc
22
) or with an OGA inhibitor 
(GlcNAcstatin G
23
). Within 30 minutes of treatment with either inhibitor, changes in the O- 
GlcNAc levels in the CTLs were apparent. O-GlcNAc levels decreased in cells treated with 
the OGT inhibitor, and O-GlcNAc levels increased in CTLs treated with the OGA inhibitor 
(Fig. 2m). Intriguingly, inhibition of OGA lead to a maximal increase in O-GlcNAc levels of 
~1.5-fold, even with longer incubation times (Fig. 2m), whereas OGT inhibition lead to a 
near complete loss of O-GlcNAc staining within 24 hours. These data suggest that CTLs have 
close to saturating amounts of protein O-GlcNAcylation and reveal the dynamic nature of 
protein O-GlcNAcylation in T cells. 
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Protein O-GlcNAcylation during thymocyte -selection 
 
Having established that O-GlcNAc levels increased following TCR activation of peripheral T 
cells, we next explored the link between metabolism and intracellular protein O- 
GlcNAcylation during thymocyte development. In particular, we wished to investigate 
whether the increased glucose metabolism that is controlled by Notch signaling in T cell 
progenitors
24  
was associated with changes in protein O-GlcNAcylation. T cell progenitors 
that lack expression of the MHC co-receptors CD4 and CD8 (double-negative (DN) 
thymocytes) initiate rearrangements of their Tcrb locus and if successful, produce a TCR 
chain that permits pre-TCR complex expression. This stage of T cell development occurs in 
DN3 thymocytes (CD4
-
CD8
-
CD44
-
CD25
+
). The pre-TCR, in combination with Notch and 
IL-7, promotes the proliferation and differentiation of DN3s into the DN4 stage of pre-T cell 
development (CD4
-
CD8
-
CD44
-
CD25
-
), a process known as -selection25,26. -selected DN4 
cells then undergo rapid self-renewal and differentiate into CD4
+
CD8
+
double-positive (DP) 
thymocytes. The rapid proliferation of -selected DN4s is fueled by regulated changes in the 
metabolism of these cells
27
. Indeed, DN3 thymocytes have low rates of glucose and glutamine 
uptake whereas -selected DN4 thymocytes upregulate both glucose and glutamine 
transport; DPs return to a state of very low levels of glucose and glutamine uptake (Fig. 3a). 
Interestingly, there was a concomitant dynamic regulation of protein O- GlcNAcylation 
during these stages of thymocyte development (Fig. 3b). Protein O- GlcNAcylation was 
upregulated as DN3 thymocytes differentiated to -selected DN4 thymocytes. The further 
differentiation of -selected cells to DPs was accompanied by a striking reduction of protein 
O-GlcNAcylation (Fig. 3b). 
The metabolic changes that support the DN-to-DP stage of thymocyte differentiation are 
controlled by Notch
24,28
. We therefore wanted to address the role of Notch ligands in regulating 
protein O-GlcNAcylation in thymocytes. Hence, we used the OP9-DL1 system of in vitro 
thymocyte differentiation
29 
where OP9 cells expressing the Notch ligand delta-like 1 (DL1) 
support the differentiation and self-renewal of -selected DN3 thymocytes. This in vitro 
model recapitulates the in vivo scenario where Notch drives the rapid proliferation/self- renewal 
of TCR expressing DN4s and supports their differentiation to DPs25,30,31. DN thymocytes 
maintained in IL-7 on OP9 had low rates of glucose and glutamine transport which 
contrasted with the high rates of glucose and glutamine uptake in Notch-stimulated cells on 
OP9 DL1 (Fig. 3c). In parallel with changes in glucose and glutamine transport, DN 
thymocytes stimulated with Notch ligands increased intracellular protein O-GlcNAcylation 
(Fig. 3d). Similar to the in vivo data, as thymocytes differentiated to DPs on OP9-DL1, they 
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reverted to low intracellular O-GlcNAcylation (Fig. 3e). Thus, trophic Notch signals control 
OGT mediated protein O-GlcNAcylation in T cell progenitors in the thymus. 
 
O-GlcNAcylation in Notch-induced pre-T cell self-renewal 
Analysis of protein O-GlcNAcylation during T cell development indicated that this 
modification was tightly regulated by metabolic changes during the DN3-DN4 stages. To 
explore the importance of protein O-GlcNAcylation in pre-T cells, we generated Ogt
fl/fl
Lck- 
Cre mice. Lck-Cre expression permits deletion of OGT in the DN progenitor stage of 
thymocyte development. Thymocyte numbers in Ogt
fl/fl
Lck-Cre
+ 
mice were reduced by ≥ 
70% (Fig. 4a), due to the drastic reduction of DPs and positively selected CD4-SP or CD8- 
SP thymocytes caused by OGT loss (Fig. 4b,c). Ogt
fl/fl
Lck-Cre
+ 
mice also had a striking 
reduction in mature T cells in the periphery indicative of failed thymocyte development 
(Supplementary Fig. 1a). Intracellular staining with the RL2 antibody confirmed loss of 
protein O-GlcNAcylation in DN4 and DP thymocytes from Ogt
fl/fl
Lck-Cre
+ 
mice (Fig. 4d). 
The phenotype of Ogt
fl/fl
Lck-Cre
+ 
thymi was consistent with a failure of -selection. 
However, DN4 cells from Ogt
fl/fl
Lck-Cre
+ 
mice expressed normal levels of intracellular 
TCRsubunits indicating that they had successfully rearranged their Tcrb locus (Fig. 4e). 
Thymocyte subsets from Ogt
fl/fl
Lck-Cre
+ 
mice also expressed normal levels of Notch1, Notch2 
and IL-7R (Supplementary Fig. 1b), and there were comparable DN4 thymocyte numbers 
in Ogt
fl/fl
Lck-Cre
+ 
mice and wild-type mice (Supplementary Fig. 1c). The failure to produce 
normal numbers of DPs from TCR-expressing DN4s could reflect a failure of 
differentiation or a failure of clonal expansion. It has also been proposed that loss of OGT 
might cause increased apoptosis of DP thymocytes
12
. To distinguish these possibilities we 
examined the ability of DN thymocytes from Ogt
fl/fl
Lck-Cre
+ 
mice to differentiate and 
proliferate on  OP9-DL1  feeder  cells.  DN  cells  from  Ogt
fl/fl
Lck-Cre
+ 
mice  were  able  to 
differentiate to DPs when cultured on OP9-DL1 or OP9 cells (Fig. 4f,g). Moreover, OGT- 
null DN thymocytes survived normally when cultured in the presence of IL-7 on the OP9 
feeder cells lacking DL1 (Fig. 4h). However, in contrast to wild-type DNs, they failed to 
proliferate in response to IL-7 and DL1 (Fig. 4i). The loss of OGT thus did not prevent T cell 
progenitors from surviving or differentiating to the DP stage of thymocyte development. 
Rather, OGT was required for the rapid self-renewal of TCR-selected cell progenitors. 
 
Malignant transformation of T cell progenitors needs OGT 
T cell progenitors can undergo transformation to produce T cell leukemia/lymphoma upon 
deletion of tumor suppressors or oncogene expression
32,33
. Transformed cells are known to 
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have high rates of glucose transport. We therefore wanted to explore the protein O- 
GlcNAcylation characteristics of transformed T cell progenitors. Pten
fl/fl
Lck-Cre
+ 
mice serve 
as a murine model for T-cell acute lymphoblastic leukemia (T-ALL)
34,35
. Pten deletion in T 
cell progenitors in Pten
fl/fl
Lck-Cre
+ 
mice results in the development of aggressive, fatal T cell 
lymphomas in the thymus around 8-12 weeks after birth
33,35
. These transformed cells are 
dependent on Notch1- or c-Myc-induced signals
27
. T lymphoma cells isolated from 
Pten
fl/fl
Lck-Cre
+ 
mice had very high levels of glucose and glutamine uptake compared to non- 
transformed thymocytes (Fig. 5a,b). These high levels of glucose and glutamine uptake 
translated to high levels of O-GlcNAcylation in the transformed cells compared to wild-type 
thymocytes (Fig. 5c). We assessed the importance of intracellular protein O-GlcNAcylation 
for T cell malignancy by backcrossing the Pten
fl/fl
Lck-Cre mice with Ogt
fl/fl 
mice to generate 
mice that lacked both PTEN and OGT in T cell progenitors (Pten
fl/fl
Ogt
fl/fl
Lck-Cre). As 
described
35
, Pten
fl/fl
Lck-Cre
+  
mice had a median survival age of ~12-13 weeks (Fig. 5d). 
There was however a striking difference in survival of Pten
fl/fl
Lck-Cre
+ 
mice versus 
Pten
fl/fl
Ogt
fl/fl
Lck-Cre
+ 
(DKO) mice. Remarkably, deletion of Ogt completely rescued mice 
from PTEN-deficiency induced morbidities, and all mice (n=10) survived >30 weeks, at 
which point they were culled for analysis (Fig. 5d). Thymocyte numbers were still vastly 
lower in DKO versus wild-type mice (Fig. 5e) and the cells were unable to differentiate into 
CD4SP or CD8SP (Fig. 5f). The deletion of Pten could thus not overcome the thymus 
developmental block caused by OGT loss. Moreover, Pten deletion could not induce the 
malignant transformation of OGT-null T cell progenitors, despite the DKO mice having 
normal numbers of pre-T cells. 
 
Dynamic O-GlcNAcylation in thymocyte positive selection 
The purpose of the rapid self-renewal of -selected DN4 thymocytes is to create a pool of DP 
thymocytes that can then rearrange their Tcra locus. If rearrangements are successful, a 
functional TCRcomplex is expressed on DPs that can recognize self-antigen-MHC 
complexes. DP thymocytes can then be activated by TCR-mediated signals to differentiate to 
CD4SP or CD8SP cells (positive selection). TCR triggering of peripheral T cells increases 
intracellular protein O-GlcNAcylation. Therefore we asked whether protein O- 
GlcNAcylation was also regulated during thymocyte positive selection. TCRhiCD69+cells 
define positively selecting DPs and TCRhiCD69loCD24lo cells define mature SP cells that 
are ready to exit the thymus to populate the periphery. We found that O-GlcNAc levels 
increased as DP thymocytes respond to TCR-driven positive selection signals and 
upregulated CD69 and TCR expression (Fig. 6a). Moreover, as the cells differentiated to 
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mature CD4SP or CD8SP thymocytes they upregulated their protein O-GlcNAcylation levels 
even further (Fig. 6a). 
To explore the functional significance of the increase in protein O-GlcNAcylation that 
accompanied the differentiation of DP thymocytes to CD4SP and CD8SP cells, we generated 
Ogt
fl/fl
Cd4-Cre
+ 
mice. Cd4-Cre deletes just before the DP stage in the thymus. We found 
normal numbers of DP thymocytes in Ogt
fl/fl
Cd4-Cre
+  
mice (Fig. 6b, Supplementary Fig. 
2b). However, Ogt
fl/fl
Cd4-Cre
+ 
mice failed to produce SP thymocytes or mature T cells (Fig. 
6b-d, Supplementary Fig. 2c). We confirmed that the DP thymocytes that were present in 
normal numbers in Ogt
fl/fl
Cd4-Cre
+ 
mice had lost OGT (Fig. 6e), indicating that OGT was 
not necessary for DP survival. Moreover, these cells were able to initiate positive selection 
and upregulate CD69, a marker of successful engagement of the TCR with positively 
selecting TCR ligands (Fig. 6f). However, the OGT-null DP thymocytes could not complete 
positive selection and differentiate to TCRhi mature SP thymocytes (Fig. 6f). Thus protein 
O-GlcNAcylation is both dynamic and essential during thymocyte positive selection. 
 
The role of OGT in mature T cell clonal expansion 
No mature T cells were generated in either Ogt
fl/fl
Lck-Cre
+ 
or Ogt
fl/fl
Cd4-Cre
+ 
mice. 
Therefore, to address the role of OGT in T cell function, we generated an inducible mouse 
model for OGT deletion. We backcrossed Ogt
fl/fl 
mice with Tamox-Cre mice that 
constitutively express a hydroxytamoxifen-regulated Cre recombinase. This model permits 
rapid deletion of floxed alleles following treatment of cells with 4-hydroxytamoxifen (4- 
OHT). 4-OHT mediated deletion of OGT in naïve T cells from Ogt
fl/fl
Tamox-Cre
+ 
mice 
prevented antigen receptor-induced proliferative expansion (Fig. 7a). We also generated 
CTLs from Ogt
fl/fl
Tamox-Cre
+ 
mice and treated these cells with 4-OHT to delete the floxed 
OGT alleles directly in effector CTLs. The loss of OGT and protein O-GlcNAcylation was 
confirmed by immunoblotting (Supplementary Fig. 3). Clonal expansion of CTLs is 
controlled by the cytokine IL-2. OGT-null CTLs survived in IL-2 but failed to proliferate 
(Fig. 7b). IL-2 controls CTLs via signaling pathways mediated by STAT5, mTORC1 and c- 
Myc
19,36,37
. The loss of OGT did not impair IL-2-induced phosphorylation of STAT5 or IL-2- 
driven mTORC1 activity (Fig. 7c). In contrast, loss of OGT in CTLs resulted in loss of c- 
Myc expression (Fig. 7c). To further explore the correlation between protein O- 
GlcNAcylation and c-Myc expression in T cells we used a GFP-c-Myc knockin mouse model 
(GFP-Myc
KI
)
38 
to examine the impact of OGT and OGA inhibitors on c-Myc expression. 
TCR-activated T cells expressed high levels of c-Myc
37
, but c-Myc expression levels were 
much lower when T cells were activated in the presence of an OGT inhibitor (Fig. 7d). 
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Conversely, when T cells were activated in the presence of an OGA inhibitor, c-Myc 
expression increased (Fig. 7d). c-Myc expression in T cells is regulated post-translationally 
by GSK3-mediated phosphorylation of c-Myc Thr58, a modification that targets c-Myc for 
proteolytic degradation
37
. However, c-Myc can also be O-GlcNAcylated on Thr58 (ref. 39), 
which would prevent phosphorylation on this site and stabilize c-Myc protein. The sensitivity 
of Myc expression to OGT/OGA activity is consistent with c-Myc O-GlcNAcylation playing 
a role in controlling c-Myc expression in T cells. Indeed c-Myc could be affinity purified 
from CTLs lysates with succinylated wheat germ agglutinin (sWGA) which selectively binds 
to GlcNAcylated proteins (Fig. 7e). Moreover, the RL2 antibody could detect GFP-Myc 
immune-purified from CTLs lysates, but this RL2 immuno-reactivity was lost when GFP- 
Myc was immune-purified from CTLs lysates pre-treated with CpOGA to remove O-GlcNAc 
(Fig. 7f). c-Myc is thus O-GlcNAcylated in T cells and its expression is regulated by OGT. 
 
Glucose, glutamine supply regulate protein O-GlcNAcylation 
 
High levels of protein O-GlcNAcylation were found in T cells with high levels of glucose 
and glutamine uptake that fuel the production of UDP-GlcNAc. However, the sensitivity of 
protein O-GlcNAcylation to nutrient supply in T cells has not been explored. When CTLs 
were cultured in medium with decreasing amounts of glucose or glutamine, protein O- 
GlcNAc levels were correspondingly reduced (Fig. 8a), and a similar pattern was seen in 6 
hour activated T cells (Fig. 8b). TCR-induced increases in glucose and glutamine uptake are 
regulated by c-Myc, which controls expression of the key glucose and glutamine 
transporters
5
. We therefore explored the role of c-Myc in mediating TCR-induced changes in 
intracellular protein O-GlcNAcylation using T cells from Myc
fl/fl
Cd4-Cre
+ 
mice that have T 
cell-selective deletion of c-Myc. In resting naïve T cells, levels of protein O-GlcNAcylation 
were comparable between wild-type and Myc
fl/fl
Cd4-Cre
+ 
mice. However only TCR-activated 
wild-type but not c-Myc-null T cells were able to upregulate protein O-GlcNAcylation (Fig. 
8c). 
We previously showed that adding glucosamine to glucose-deprived cells rescues UDP- 
GlcNAc. In immune-activated primary T cells we found that glucosamine could rescue the 
loss of protein O-GlcNAcylation induced by lack of glucose or glutamine (Fig. 8d). The 
expression of c-Myc, but not activation markers such as CD69, was similarly regulated by 
glucose and glutamine supply (Fig. 8e,f). TCR-activated T cells could thus not sustain 
expression of c-Myc or the Myc-regulated transferrin receptor
37  
(CD71) in the absence of 
exogenous glucose and glutamine. Importantly, the direct supply of glucosamine, that directly 
fuels UDP-GlcNAc production could restore global protein O-GlcNAcylation, c-Myc 
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and transferrin receptor expression in glucose and glutamine starved activated T cells (Fig. 
8d-g). Collectively these data show that glucose and glutamine supply fuel protein O- 
GlcNAcylation in T cells via the HBP, which in turn regulates c-Myc expression levels in a 
feedback loop. 
 
Discussion 
The present study has shown that T cells exhibit dynamic regulation of intracellular protein 
O-GlcNAcylation at key stages of development in the thymus, following immune challenge 
by pathogen in vivo, and as a direct response to TCR engagement with cognate peptide. There 
are also striking changes in protein O-GlcNAcylation in malignant T lymphoma cells. These 
changes in protein O-GlcNAcylation are fueled by regulated changes in glucose and 
glutamine supply and are balanced by the cellular activities of OGT, and the glycosidase 
OGA. OGT was shown to be critical for Notch mediated self-renewal and malignant 
transformation of -selected T cell progenitors during thymus development. OGT is also 
required for thymocyte positive selection and to initiate and sustain the clonal expansion of 
immune activated peripheral T cells. The present study thus affords the insight that glucose 
and glutamine flux through the HBP to generate UDP-GlcNAc, the substrate for OGT- 
mediated protein O-GlcNAcylation, is regulated by antigen receptor engagement. OGT- 
mediated protein O-GlcNAcylation is a critical process for T cell function. 
It is increasingly recognized that T cell metabolism may be compromised during chronic viral 
infections and in T cells within tumors, thus contributing to a state of T cell ‘exhaustion’ that 
prevents T cells exerting their effector function
40-42
. This may be particularly problematic 
when  T  cells  are  in  microenvironments  that  are  hypoxic
40   
or  where  there  is  strong 
competition for nutrients such as glucose
41,42
. So far the glucose requirements of activated T 
cells have been studied primarily in the context of glucose as a fuel for oxidative 
phosphorylation and glycolysis and as a building block for nucleotide and amino acid 
biosynthesis, while glutamine metabolism studies have mainly focused on protein synthesis 
and glutaminolysis. The present study shows that glucose and glutamine availability also 
dictates the crucial process of protein O-GlcNAcylation. OGT thus functions to integrate 
changes in glucose and glutamine supply to modify T cell biology. OGT acts as a master 
regulator that depends on nutrient levels to control the commitment of T cells to 
metabolically demanding processes of clonal expansion, self-renewal and differentiation. 
OGT acts in the thymus as a checkpoint for Notch mediated control of T cell progenitors. It 
also acts as a checkpoint for TCR-mediated positive selection and for TCR-induced clonal 
expansion of peripheral T cells. 
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One experimental observation that would explain some of the phenotypes of OGT-null cells 
was the impact of OGT deletion on the expression of c-Myc. This proto-oncogene has a key 
role to control metabolism of thymocytes and peripheral T cells
5
. In the absence of c-Myc, 
triggering of the TCR in peripheral T cells is unable to sustain increases in protein O- 
GlcNAcylation. Conversely we noted that OGT inhibition or deletion was associated with a 
failure of activated T cells to sustain expression of c-Myc. In this context we show that c- 
Myc is O-GlcNAcylated in T cells and that its expression is regulated by glucose availability. 
This ability of c-Myc to function as a glucose sensor in T cells reflects that glucose fuels 
protein O-GlcNAcylation, and O-GlcNAcylation of c-Myc promotes c-Myc stabilization. 
Collectively the present study reveals an essential positive feedback loop linking OGT- 
mediated pathways of protein O-GlcNAcylation in T cells to c-Myc expression. The failure 
to sustain c-Myc expression would explain the failure of OGT null T cell progenitors to self- 
renew or undergo malignant transformation
43,44 
and would explain why OGT-null peripheral 
T cells fail to clonally expand. However, the effects of OGT on c-Myc are not sufficient to 
explain all the functions of OGT in T cells. For example, only loss of OGT, but not c-Myc, at 
the DP stage of thymus development blocks positive selection of mature SP T cells
45
. In this 
respect, immunoblot analyses herein reveal the complexity of protein O-GlcNAcylation in T 
cells indicating that there are many OGT substrates in T cells. Studies in transformed T cells 
have identified the transcription factors NFκB and NFAT as OGT substrates15,16. The present 
data reveal the complexity and dynamic nature of the intracellular O-GlcNAcylated T cell 
proteome and this is likely to be similar to the complexity of protein phosphorylation pathways. 
The diversity of T cell functions controlled by OGT thus make it probable that the importance 
of OGT for T cells will be linked to O-GlcNAcylation of multiple targets. In summary, 
these data highlight the complex roles of protein O-GlcNAcylation for T cell signaling: 
a previously underappreciated function of T cell nutrient metabolism. The importance of 
OGT is tightly linked to the metabolically demanding processes of T cell self- renewal and 
clonal expansion. OGT thus acts as signaling hub to integrate T cell responses to developmental 
and immune activating stimuli that increase rates of glucose and glutamine transport in T 
cells. 
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Figure legends 
 
Figure 1. T cells utilize glucose and glutamine intake for UDP-GlcNAc biosynthesis through 
a key nutrient-sensing pathway. (a) Uptake of 
3
H-2-deoxyglucose or 
3
H-glutamine by naïve 
lymph node (LN) T cells maintained in IL-7 (IL-7) (n=2 mice) or TCR stimulated with 
CD3/CD28 antibodies for 24 hours (n=3 mice). (b) Uptake of 
3
H-2-deoxyglucose or 
3
H- 
glutamine by effector CD8
+ 
T cells (CTL) or CD4
+ 
T helper cells (TH1) or naïve T cells 
maintained in IL-7 for 24 hours (IL-7). (c) Glucose and glutamine intake feed into the 
hexosamine biosynthesis pathway that produces UDP-N-Acetylglucosamine (UDP-GlcNAc), 
which is the substrate for OGT. Glucosamine bypasses the rate-limiting step of synthesis of 
glucosamine-6-phosphate, and the requirement for glucose and glutamine to make UDP- 
GlcNAc. (d-g) UDP-GlcNAc concentrations measured by LC-MS/MS (n=3 mice each). (d) 
UDP-GlcNAc in naïve (0 h) CD8
+ 
T cells, OT-I T cells (24 h) and CTLs. (e) UDP-GlcNAc 
in naïve (0 h) CD4
+ 
T cells, CD3/CD28 stimulated CD4
+ 
T cells (24 h) and TH1 effectors. (f) 
UDP-GlcNAc concentrations in OT-I T cells either unstimulated (maintained in IL-7, IL-7) 
or activated for 24 hours with peptide in full medium or medium lacking either glucose (-Glc) 
or glutamine (-Gln). (g) UDP-GlcNAc concentrations in OT-I cells stimulated in medium 
supplemented as indicated. *P < 0.05, ** P < 0.01, *** P < 0.001 (one-way ANOVA, n=3 
mice each). Data are from one experiment representative of 3 (a, mean and s.e.m. of biological 
replicates), 4 (b, mean and s.e.m. of technical replicates, n=1), and one experiment each (d-g). 
 
Figure 2. TCR activation upregulates O-GlcNAcylation in T cells. (a) Immunoblot analysis 
of O-GlcNAc in naïve (–) and 24 hours CD3/CD28-activated (+) T cells (n=2 mice). (b) 
Immunoblotting of CTLs lysates either untreated (lanes 1,3,4) or treated with CpOGA (lane 
2). Immunoblotting was with the O-GlcNAc antibody (lanes 1,2), or the antibody was pre- 
incubated with 0.5 M N-Acetylglucosamine (GlcNAc) (lanes 3,4). (c) Intracellular flow 
cytometric analysis with an O-GlcNAc antibody (RL2) of CTLs and naïve CD8
+ 
T cells. (d) 
Flow cytometric analysis of naïve CD8
+ 
T cells with the O-GlcNAc antibody that was either 
pre-incubated with free N-Acetylglucosamine (+GlcNAc) or not. (e) O-GlcNAc flow 
cytometric analysis of CTLs treated with CpOGA. (f) Dot plot showing forward scatter 
(FSC) and O-GlcNAc intensities of cells derived from CTLs (grey) and TH1 (black) cultures 
(n=1 mouse). Pearson's correlation=-0.072 (CTL), 0.036 (TH1). (g) 6 hour activated OT-I T 
cells were either fixed, permeabilized and analyzed, or live cells were analyzed for O- 
GlcNAc flow cytometry. (h) Naïve LN T cells (n=3 mice) were stimulated with CD3/CD28 
antibodies for 6, 24 or 48 hours, and their O-GlcNAc mean fluorescence intensities (MFI) 
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were normalized as a fractional difference to naïve resting T cells (gated on CD62L
hi
, 
CD44
lo
). (i) O-GlcNAc flow cytometry data normalized as in (h) of OT-I CD8
+ 
T cells 
stimulated for 24 hours with OVA-derived peptides. O-GlcNAc MFI of total CD8
+ 
T cells 
was normalized to the MFI of unactivated cells (n=4 mice, pooled from 2 experiments). (j) 
O-GlcNAc MFI (normalized to naïve cells) of OT-I T cells stimulated with serial dilutions of 
Q4 peptide for 6 hours (n=3 mice). (k-l) O-GlcNAc flow cytometric analysis in CD69
+ 
or 
CD69
– 
splenic CD4
+ 
(k) and CD8
+ 
(l) T cells isolated from mice (n=5) infected i.v. with 
Listeria. (m) Normalized (to untreated) O-GlcNAc MFI in CTLs treated for the indicated 
times with an OGA inhibitor (OGAi) or an OGT inhibitor (OGTi). *P < 0.05, **P < 0.01, 
***P < 0.001 (h, One-way ANOVA, compared to 0 h time point, k,l, paired t-test). Data are 
representative of 2 similar experiments (a) 1 experiment (b), 3 experiments (h,i,j, mean ±s.d. 
shown), experiments shown in c-g are representative of at least 5 experiments, (m) left, mean 
(±s.d.) of n=5 cultures from 2 experiments shown, right, n=1, representative of 2 
experiments. 
 
Figure 3. Glucose and glutamine uptake are regulated during thymocyte -selection and feed 
into O-GlcNAcylation. (a) Uptake of 
3
H-2-deoxyglucose and 
14
C-glutamine in thymocytes 
pooled from 10 wild-type mice sorted into DN3, DN4 and DP subsets. (b) Intracellular flow 
cytometric analysis of O-GlcNAc and TCRwas done along with surface markers for the 
different subsets (n=6 mice). (c) DN3-4 thymocytes were cultured on OP9 or OP9-DL1 in the 
presence of IL-7 (5 ng/ml) for 2 days. Uptake of 
3
H-2-deoxyglucose and 
14
C-glutamine was 
measured, as well as (d) intracellular O-GlcNAc levels in either total Thy1
+ 
cells on OP9 or 
OP9-DL1, or (e) cells grown on OP9-DL1 and gated on DP (CD4
+
CD8
+
) and DN (CD4
-
CD8
-
 
) thymocytes. ***P < 0.001 (One-way ANOVA). Data are from 1 experiment (a), 2 pooled 
experiments and representative of 5 similar experiments (b), 1 experiment representative of 3 
independent experiments (c,d,e). 
 
Figure 4. Loss of OGT at the DN stage of T cell development leads to a strong block in T 
cell development. (a) Total numbers of cells isolated from thymi of Ogt
wt/wt
Lck-Cre
+ 
mice 
(n=21) and Ogt
fl/Y or fl/fl
Lck-Cre
+ 
mice (n=21) are plotted. (b) Representative flow cytometry 
of CD4 and CD8 expression on Thy1
+ 
thymocytes from Ogt
wt
Lck-Cre
+  
and Ogt
fl/Y
Lck-Cre
+ 
mice from (a). (c) Quantification of thymic subsets in 6- to 12-week old Ogt
wt/wt
Lck-Cre
+ 
(n=9) and Ogt
fl/Y or fl/fl
Lck-Cre
+ 
mice (n=9). (d) Flow cytometric histogram plots showing 
intracellular O-GlcNAc levels in Ogt
wt/wt
Lck-Cre
+ 
(WT) and Ogt
fl/Y
Lck-Cre
+ 
(KO) DN4 and 
DP subsets. (e) Intracellular flow cytometry for TCR(pre-TCR) in DN3 and DN4 subsets 
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from Ogt
wt/wt
Lck-Cre
+ 
and Ogt
fl/Y
Lck-Cre
+ 
thymi. (f-i) OGT
wt/wt
Lck-Cre
+ 
and Ogt
fl/Y
Lck-Cre
+ 
DN thymocytes were cultured for 6 days on OP9 or OP9-DL1 feeder cells, in the presence or 
absence of 5 ng/ml IL-7. 3 days after culture on OP9-DL1 (f) or OP9 (g), Ogt
wt/wt
Lck-Cre
+ 
and Ogt
fl/Y
Lck-Cre
+ 
thymocytes were stained for CD4 and CD8. (h,i) Proliferation of 
Ogt
wt/wt
Lck-Cre
+ 
and Ogt
fl/Y
Lck-Cre
+ 
DN thymocytes cultured on OP9 (h) or OP9 -DL1 (i) 
feeders in the presence of 5 ng/ml IL-7. NS, not significant (P=0.251), ***P < 0.001, ****P 
< 0.0001 (unpaired t-test (a), Mann-Whitney Rank Sum test (c)). Data are cumulative (a,c) or 
representative of >40 mice (b), 3 mice (d), 3 mice (e) and (f-i) are representative of 3 
independent experiments. 
 
Figure 5. Loss of OGT prevents transformation of PTEN-null thymocytes. Analysis of (a) 
3
H-2-deoxyglucose uptake and (b) 
3
H-glutamine uptake in cells isolated from thymi of 
Pten
fl/fl
Lck-Cre
– 
and from thymic tumors of Pten
fl/fl
Lck-Cre
+ 
mice (n=1). (c) Immunoblot 
analysis of global O-GlcNAcylation and OGT in equal numbers of thymic lymphoma cells 
from two representative Pten
fl/fl
Lck-Cre
+ 
mice and total thymocytes from two Pten
fl/fl
Lck- 
Cre
– 
mice. SMC1 was used as loading control. (d) Kaplan-Meier survival plot comparing 
kinetics of tumor development in Pten
fl/fl
Lck-Cre
+ 
(n=8) mice compared with Pten
fl/fl
Ogt
fl/fl or 
fl/Y
Lck-Cre
+ 
(n=10) mice. (e) Average thymocytes numbers in old Pten
fl/fl
Ogt
fl/fl or fl/Y
Lck-Cre
+
 
mice (n=8, average age=239 days), as compared to wild-type (WT) mice of similar age 
(n=3). (f) Representative flow cytometric plots of CD4 and CD8 expression in Thy1
+ 
thymocytes derived from Pten
fl/wt
Ogt
wt
Lck-Cre
+ 
and Pten
fl/fl
Ogt
fl/Y
Lck-Cre
+ 
thymi at 6 weeks 
of age. ***P = 0.000228, ****P < 0.0001 (Log rank (Mantel-Cox) test (d), unpaired t-test 
(e)). Data are from one experiment, representative of 3 (a-c), cumulative (d,e), and 
representative of 3 mice (f). 
 
Figure 6. Deletion of OGT at the DP stage of T cell development blocks positive selection. 
(a) O-GlcNAc flow cytometric analyses in quiescent DPs (TCRloCD69–), pre-selected 
(TCRloCD69hi), post-selected (TCRhiCD69hi) thymocytes, and mature CD4SP and CD8SP 
(TCRhiCD69loCD24lo). Populations were electronically gated as depicted in Supplementary 
Fig. 2a. (b) Quantification of thymic subsets cell numbers in 6- to 12-week old Ogt
wt/wt
Cd4- 
Cre
+ 
(n=4) and Ogt
fl/fl
Cd4-Cre
+ 
mice (n=4). (c) Representative flow cytometry plots of CD4 
and CD8 expression on Thy1
+ 
thymocytes from Ogt
wt/Y
Cd4-Cre
+ 
and Ogt
fl/Y
Cd4-Cre
+ 
mice. 
(d) Total numbers of TCR+ cells isolated from Ogtwt/wtCd4-Cre+ spleens (n=9) and 
Ogt
fl/fl
Cd4-Cre
+ 
spleens (n=9) are plotted. (e) Immunoblotting analysis of OGT and loading 
control SMC1  for thymocytes  from  3 Ogt
wt/Y
Cd4-Cre
+   
and 3  Ogt
fl/Y
Cd4-Cre
+   
mice. (f) 
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Representative flow cytometry for TCRexpression and CD69 expression in WT and KO 
thymocytes (gated on Thy1
+ 
living cells). To the right, histogram of TCR expression is 
shown in Ogt
wt/Y
Cd4-Cre
+ 
(n=1) and Ogt
fl/Y
Cd4-Cre
+ 
(n=3) thymocytes. NS, not significant, 
** P=0.00437, ***P < 0.001, **** P < 0.0001 (One-way ANOVA (a), t- tests (b, mean ± 
s.e.m), Mann-Whitney Rank Sum test (d)). Data are cumulative (a,b,d), representative of 9 
mice (c,f), and one experiment (e). 
 
Figure 7. Protein O-GlcNAcylation regulates c-Myc expression and T cell clonal expansion. 
(a,b) Total numbers of cells obtained on each day of primary CTLs cultures of splenic T cells 
from Ogt
wt
Tamox-Cre
+ 
or Ogt
fl/Y
Tamox-Cre
+ 
mice. In (a), naïve splenocytes were treated 
with 4-OHT for 4 hours prior to washing out and activation. In (b) 4-OHT treatment was 
done on day 5. (c) Cells cultured as in (b) were immunoblotted as indicated. (d) GFP-Myc
KI 
LN T cells (n=5 mice) were stimulated for 6 hours with CD3/CD28 antibodies in  the presence 
of an OGA or an OGT inhibitor (OGAi, OGTi). GFP-myc MFI normalized to naïve T cells is 
plotted. (e) sWGA affinity purification (AP) from OT-I CTLs lysates were analyzed by 
immunoblotting for c-Myc. The cell lysate were either left untreated or treated with 
CpOGA before the affinity purification and immunoblotting for c-Myc and OGT. Total 
lysates were probed for total protein O-GlcNAcylation and c-Myc. (f) GFP immune- 
purification (IP) was done from GFP-Myc
KI 
CTLs lysate that were either left untreated or 
CpOGA treated. Immune-purified GFP-Myc was probed with RL2 antibody. The lysates 
were immunoblotted for total protein O-GlcNAcylation and c-Myc. *P = 0.017, ** P < 0.001 
(one-way ANOVA). Data are from one experiment each (a,b, mean ± s.d. n=3 mice for each 
genotype) and representative of 2 (a) and 5 (b) experiments, data are from 2 pooled 
experiments (d), and data in (c,e,f) are from one experiment and representative of 2 (c), 2 (e) 
and 4 (f) experiments. 
 
Figure 8. c-Myc regulates protein O-GlcNAcylation through glucose and glutamine flux. (a) 
O-GlcNAc flow cytometric analyses in day 7 CTLs (n=6 mice) cultured for 20 hours in 
RPMI containing different doses of glucose or glutamine in the medium. O-GlcNAc MFI was 
normalized to the MFI of CTLs grown in the highest concentration of glucose or glutamine. 
(b) O-GlcNAc flow cytometric analyses in 6 hours activated OT-I T cells (n=3  mice) cultured 
in RPMI containing different doses of glucose or glutamine in the medium, normalized as in 
(a). (c) O-GlcNAc flow cytometric analysis in total live CD8
+ 
T cells from LN of Myc
fl/fl
Cd4-
Cre
–  
(n=3) and Myc
fl/fl
Cd4-Cre
+  
(n=3) mice, stimulated with CD3/CD28 
antibodies for 18 hours (+), or fixed directly post-isolation (–). (d-g) GFP-mycKI LN T cells 
22  
(n=6 mice) were activated for 6–24 hours in either complete medium, or in medium lacking 
glucose (-Glc) supplemented or not with glucosamine (+GlcN), or lacking glutamine (-Gln) 
supplemented or not with glucosamine (+GlcN). (d) O-GlcNAc MFI measured by 
intracellular flow cytometry after 6 hours and normalized (n=6) to unstimulated cells. (e) 
GFP-myc fluorescence intensity measured after 6 hours and normalized to unstimulated cells. 
(f) CD69 MFI measured after 6 hours, and (g) CD71 MFI (n=3 mice) measured after 24 
hours, were normalized to cells stimulated in full medium. NS, not significant, *P < 0.05, 
**P < 0.01, ***P < 0.001 (one-way ANOVA). Data are pooled from 2 experiments (a, mean 
± s.e.m of n=6 (glucose) n=5 (glutamine)) and representative of 2 experiments (a) or one 
experiment (b, mean ± s.d. of n=3), one experiment (c) or pooled from 2 experiments (d-g, 
mean ± s.d.). 
23  
Online Methods 
 
Mice 
 
All mice were maintained in the University of Dundee in compliance with UK Home Office 
Animals (Scientific Procedures) Act 1986 guidelines. C57BL/6J mice, Cd4-Cre (Tg(Cd4- 
cre)1Cwi/BfluJ) and Lck-Cre (Tg(Lck-cre)548Jxm) were obtained from Jackson laboratories 
and maintained in-house. Tamox-Cre mice (C57BL/6-Gt(ROSA)26Sortm9(CreESR1)Arte) were 
purchased from Taconic.The OT-I TCR transgenic mice express a TCR recognizing the 
ovalbumin (OVA) derived peptide SIINFEKL. Myc
fl/fl
Cd4-Cre
+ 
and control Myc
fl/fl
Cd4-Cre
-
 
were used as previously described
46
. GFP-Myc
KI 
were previously described
38
. Ogt
fl 
(B6.129- 
Ogt
tm1Gwh
/J) mice, possessing loxP restriction sites on either side of the exon encoding amino 
acids 206-232 of the X-linked Ogt gene
11
, and female mice bear two copies of the floxed 
allele while males carry one, were purchased from Jackson Laboratories. Both male and 
female mice were analyzed, unless otherwise stated in the figure legends. Pten
fl/fl
Lck-Cre mice 
were generated as described previously
33
. When studying normal PTEN-null T cells, to  
ensure the absence of transformed T cells, experiments were performed using mice between 4 
and 6 weeks of age. All mice were on a C57BL/6 genetic background and were used between 
6 and 24 weeks old. Wild-type mice used as controls were either WT or WT-Cre
+ 
or Cre 
recombinase-negative with various Pten or Ogt floxed alleles. No randomization was deemed 
necessary for any animal studies. Analyses of mice phenotypes were performed blinded, and 
genotypes assigned to the mice after analyses. 
 
Primary T cell cultures 
 
For experiments involving T cell receptor (TCR) stimulation, CD3 antibody (2C11, 5 g/ml) 
and CD28 antibody (clone 37.51, eBioscience, 3 g/ml) were used for polyclonal T cell 
activation whilst OVA-derived peptides (10 ng/ml unless otherwise stated) were used for OT- 
I T cell activation for the specified times. peptides OVA peptides used were Q4H7 
(SIIQFEHL:  Kd  51±9.1  nM),  Q4R7  (SIIQFERL:  Kd  48±9.5  nM),  Q4  (SIIQFEKL:  Kd 
29±7.2 nM) and N4 (SIINFEKL: Kd 3.7±0.7 nM). Primary T cells were activated to generate 
CTLs as described previously
19
. To generate TH1 cells, CD8
+ 
T cells were depleted from 
lymph node preparations using CD8
+ 
isolation kits (Miltenyi Biotech or Stemcell 
Technologies). CD4
+ 
cells and APCs were cultured at 1×10
6 
cells/ml for 3 days in the 
presence of CD3 (5 g/ml) and CD28 (3 g/ml) antibodies and IL-12 (2 ng/ml, R&D 
Systems) and IL-2 (20 ng/ml, Proleukin), and then 2 more days in just IL-2 and IL-12. Cells 
24  
were treated with inhibitors for OGT (OGTi, 4Ac-5S-GlcNAc
22
) or OGA (OGAi, 
GlcNAcstatin G
23
) as indicated in the figure legends. Inhibitors were produced in-house. 
For nutrient starvation experiments, primary T cells were cultured in RPMI 1640 without 
glucose and glutamine (Biological Industries, USA) supplemented with 10% dialyzed FBS 
with a 10 kDa cutoff, MEM-amino acids, MEM non-essential amino acids, MEM vitamins, 1 
mM sodium pyruvate, Insulin-transferrin-selenium, 50 M β-mercaptoethanol (all from 
Thermo Fisher Scientific).  Further supplementation was  with glucose (Sigma, 10 mM), 
glutamine (Gibco, 2 mM) or glucosamine (Sigma, 100 M) unless otherwise indicated in 
figure legends. 
 
Flow cytometry and cell sorting 
 
For cell surface staining, fluorochrome-conjugated antibodies (BD were used to detect (clone 
indicated in brackets): CD4 (RM4-5), CD8 (53-6.7), TCR (H57-597), B220 (RA3-6B2), 
CD25 (PC61), CD71 (C2F2), CD98 (RC388), CD44 (IM7), CD62L (MEL-14), CD69 
(H1.2F3), (BD Biosciences) CD45.1 (104), CD45.2 (A20), c-kit (2B8), Notch1 (HMN1-12, 
1:100), (Biolegend) Notch2 (16F-11), IL-7R (A7R34, 1:100), CD24 (M1/69), and Fc Block 
(2.4G2) (eBioscience). Antibodies were diluted 1:200 unless otherwise indicated, and 1 × 10
6
 
cells were stained in 100 l. Cells were gated according to their forward scatter and side 
scatter, and dead cells excluded based on their staining with the LIVE/DEAD fixable dead 
cell staining kit (Life Technologies). 
For intracellular staining for O-GlcNAc, cells were fixed in freshly prepared 1% (vol/vol) 
paraformaldehyde for 10 min at 37 ºC, and then permeabilized in 90% (vol/vol) methanol. 
After washing, cells were incubated with AlexaFluor 647-conjugated O-GlcNAc antibody 
(RL2, Novus Biologicals, 1:800) for 20 min at 20-22 ºC. For competition based flow, the 
antibody was pre-incubated with 1 M N-Acetylglucosamine (Sigma Aldrich) prepared in PBS 
with 1% (vol/vol) FBS for 1 h before adding to the cells and incubating as described. CpOGA 
treatment (5 g of enzyme per 1 × 106 cells) was performed for 1 h at 37 ºC. Intracellular 
TCRstaining in ex vivo thymocytes was done as previously described47. Data were acquired 
on LSR Fortessa or FACSVerse or LSR Canto machines (Becton Dickinson) and analyzed 
using FlowJo software (TreeStar). 
 
Nutrient uptake measurements 
 
Nutrient uptake was carried out using 0.5–1 × 106 cells resuspended in 0.4 ml  uptake medium. 
Glucose and glutamine uptake were measured simultaneously in PBS with Ca
2+ 
and Mg
2+   
(Life  Technologies)  containing  [
3
H]-2-deoxyglucose  (0.5  Ci/ml),  and  [14C]-L- 
25  
Glutamine (0.5 Ci/ml), or individually in glucose-free RPMI (Life Technologies) containing 
[
3
H]-2-deoxyglucose (0.5 Ci/ml), and in HBSS with Ca2+ and Mg2+ (Life Technologies) 
containing [
3
H]-L-Glutamine (0.5 Ci/ml). 4 min uptake assays were carried out layered over 
0.5 ml of 1:1 silicone oil (Dow Corning 550 (BDH silicone products); specific density, 1.07 
g/ml):dibutyl phthalate (Fluka). Cells were pelleted below the oil, following which the aqueous 
supernatant and the silicon oil/dibutyl phthalate mixture were aspirated, and the cells were 
washed twice with water. The cell pellet was then lysed in 200 l NaOH (1 M) and - 
radioactivity measured by liquid scintillation counting in a Beckman LS 6500 Multi-Purpose 
Scintillation Counter (Beckman Coulter). 
 
Quantification of cellular UDP-GlcNAc concentrations 
 
Extraction and downstream processing of nucleotide sugars is based on the previously 
described method
20
. In brief, 5 × 10
6 
CD8
+ 
T cells and 1 × 10
6 
CD4
+ 
T cells were harvested 
at different time points after induction, washed with ice-cold PBS, lysed with 70% (vol/vol) 
ethanol and spiked with 20 pmol of the internal standard GDP-glucose. The samples were 
lipid-extracted with butanol and the hydrophilic phase was used for nucleotide sugar 
extraction by graphitized carbon columns (Supelclean
TM 
Envi
TM
-Carb, 3 ml, Supelco). The 
eluted and freeze dried samples were re-suspended in 40 l (CD8+) or 20 l (CD4+) of water 
and 10 l (CD8+) or 15 l (CD4+) were separated by HPLC (Ultimate 3000, Dionex) on a 
porous graphitic carbon column (HYPERCARB, 30 × 1 mm, Thermo Scientific
TM
) using a 
linear gradient of 4–20% (vol/vol) acetonitrile in 0.03% (vol/vol) formic acid (adjusted to pH 
9 with ammonia). Nucleotide sugars were detected by electrospray ionisation-tandem mass 
spectrometry (ESI-MS/MS) using multiple reaction monitoring (MRM) in negative ion mode 
on a TSQ Quantiva Triple Quadrupole Mass Spectrometer (Thermo Scientific). A standard 
master mix of nucleotide sugars with known absolute quantities was used as a reference on 
each day of analysis. In each chromatogram peaks were smoothed and areas integrated 
(Gaussian) by Xcalibur software. The cellular concentration of UDP-GlcNAc were calculated 
by using the formula: Quantity of UDP-GlcNAc [pmol] = (sample area UDP-GlcNAc / 
sample area GDP-Glc) × (standard area GDP Glc / standard area UDP-GlcNAc) × (20 pmol 
× coefficient UDP-GlcNAc); with “20 pmol” being the amount of GDP-Glc the sample has 
been spiked with and the “coefficient UDP-GlcNAc” describing a multiple of GDP-Glc of 
the actual UDP-GlcNAc concentration in the standard master mix. Accordingly, the amount 
of UDP-GlcNAc was divided by the number of cells and the total amount of molecules per 
cell calculated. 
26  
Listeria infection 
 
An attenuated Act-A deleted strain of Listeria monocytogenes that expresses OVA was 
used
48
. Wild-type mice were immunized by intravenous injection of 3 × 10
6 
colony forming 
units. Mice were culled after 3 days and spleens harvested for analysis. 
 
Immunoblotting 
 
TCR stimulated CD8
+ 
T cells were purified by magnetic separation (Stemcell Technologies) 
prior to protein extraction. Standard immunoblotting protocols were used
19
. Blots were probed 
with antibodies recognizing, dilutions and clone/catalog numbers in brackets: c-Myc (1:1000, 
#9402), pY694 STAT5 (1:2000, #9351), pan STAT5 (1:1000, #9363), pT389 S6K 
(1:1000, #9239), S6K (1:1000, #5610) (Cell Signalling Technology), SMC1 (1:5000, A300- 
055A, Bethyl), tubulin (1:5000, H-235) (Santa Cruz), OGT (1:1000, DM17, Sigma) and 
O-GlcNAc (1:3000, RL2, Abcam). Lysate made from 2 × 10
8 
day 6 CTLs were used for the 
succinylated wheat germ agglutinin (sWGA) affinity purifications. One half of the lysate was 
treated with CpOGA and other half was left untreated. Before sWGA affinity purifications, 
the lysates were precleared with agarose beads for 30 min at 4 ºC. 50 l sWGA beads (L- 
1020S, Vector Laboratories) were incubated for 16 h with the lysates and beads were washed 
4 times with PBS before adding the LDS-loading buffer. For GFP-myc immune-purification, 
2 × 10
8 
GFP-Myc
KI 
CTLs were lysed and half the lysate was treated with CpOGA or left 
untreated before the immune-purification. The lysates were incubated with GFP-binder 
agarose beads (ChromoTek) for 90 min at 4 °C. Beads were washed three times with NP40 
buffer before adding the LDS-loading buffer for immunoblotting. 
 
OP9 culture system and assays 
 
OP9 bone marrow stromal cells expressing OP9-DL1
29 
and control OP9 cells were 
maintained in alpha-MEM supplemented with 50 M 2-mercaptoethanol, 100 U/ml 
penicillin, 100 g/ml streptomycin and 20% (vol/vol) heat-inactivated FBS. Flow-sorted 
DN3 thymocytes (gated on Thy1
+
CD44
-
CD25
hi
CD4
-
CD8
-
) were cultured on OP9 or OP9- 
DL1 cells for the times indicated in the figure legends. IL-7 was added at 5 ng/ml where 
indicated. In some experiments total DNs (purified by magnetic depletion of all Lin
+ 
cells) 
were directly used. 
 
Statistical Analyses 
 
Data sets were analyzed using SigmaPlot 12.5 (Systat) or Prism 6.0 (GraphPad). A Shapiro- 
Wilk test for normality was performed to determine suitable tests for parametric or non- 
27  
parametric populations. F-tests were performed to determine equal variance of populations, 
otherwise tests assuming unequal variance were performed. All utilized tests were two-tailed 
and are stated in the respective figure legends. Multiple comparisons in one-way ANOVA 
analyses were corrected for using the Holm-Sidak method. Kaplan-Meier survival analyses 
were performed for the PTEN
fl/fl
Lck-Cre tumor model. 
 
46. Mycko, M. P. et al. Selective requirement for c-Myc at an early stage of V(alpha)14i 
NKT cell development. J. Immunol. 182, 4641–4648 (2009). 
47. Hinton, H. J., Clarke, R. G. & Cantrell, D. A. Antigen receptor regulation of 
phosphoinositide-dependent kinase 1 pathways during thymocyte development. FEBS 
Lett. 580, 5845–5850 (2006). 
48. Pearce, E. L. & Shen, H. Generation of CD8 T cell memory is regulated by IL-12. J. 
Immunol. 179, 2074–2081 (2007). 
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